{"entity":{"id":"nct04739527","kind":"trial","name":"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","aka":[],"tldr":"A phase 1 trial of Vididencel run by University Medical Center Groningen, completed.","summary":"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment is a phase 1 interventional study registered as NCT04739527 by University Medical Center Groningen, with 17 participants enrolled, started 2021-06-10. Conditions recorded: Ovarian Cancer. Interventions recorded: DCP-001.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04739527","url":"https://clinicaltrials.gov/study/NCT04739527"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["vididencel"],"companies":["mendus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04739527","phase":"1","setting":"An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","sponsor":"University Medical Center Groningen","enrolled":17,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04739527/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"vididencel","kind":"drug","name":"Vididencel","route":"/drugs/vididencel/"}],"company":[{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"}]}}